6 completed, 2 unknown, 1 not yet recruiting. 6 Phase 3, 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
| Not applicable | 2 | Unknown 2 |
Follow Prurigo: new trials by email Literature Review of Prurigo trials Research Report on Prurigo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients Lebrikizumab - Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 15 | 2026-09-01 | 2026-09-03 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Ruxolitinib Cream, Vehicle Cream - Prurigo Nodularis | Phase 3 | Completed | Incyte Corporation | 190 | 2023-06-12 | 2026-11-06 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Ruxolitinib Cream, Vehicle Cream - Prurigo | Phase 3 | Completed | Incyte Corporation | 204 | 2023-03-10 | 2026-08-12 |
| Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab 30 mg, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 286 | 2020-09-11 | 2024-07-10 |
| A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 274 | 2020-08-11 | 2024-07-10 |
| Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases Photo(chemo)therapy - Psoriasis, Cutaneous T Cell Lymphoma | Not applicable | Unknown | Medical University of Graz | 240 | 2017-10-30 | 2017-11-13 |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis nalbuphine HCl ER - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 36 | 2015-08-15 | 2025-05-21 |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 62 | 2015-03-01 | 2025-05-21 |
| Dapsone Prurigo Study Dapsone gel - verum - Lichen Simples Chronicus and Prurigo | Not applicable | Unknown | Cook County Health | 20 | 2013-09-01 | 2013-06-05 |
Pruritus (6) · Skin Diseases (5) · Dermatitis (3) · Neurodermatitis (3) · Eczema (1) · Graft vs Host Disease (1) · Lichen Planus (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoproliferative Disorders (1) · Mastocytosis (1) · Psoriasis (1) · Vitiligo (1)
Skin and Connective Tissue Diseases (9) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Skin Manifestations (6) · Dermatitis (4) · Skin Diseases (4) · Skin Diseases, Eczematous (4) · Hemic and Lymphatic Diseases (1) · Hypopigmentation (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lichenoid Eruptions (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
nemolizumab (2) · BID protein, human (1) · Nalbuphine (1) · Sugars (1) · lebrikizumab (1) · ruxolitinib (1)
Galderma R&D (2) · Incyte Corporation (2) · Trevi Therapeutics (2) · Cook County Health (1) · Medical University of Graz (1) · University of Maryland, Baltimore (1)
United States (7) · Germany (5) · Poland (5) · Canada (4) · Austria (3) · France (3) · Italy (3) · Spain (3) · Belgium (2) · Denmark (2) · Netherlands (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Australia (1)
Haq Nawaz, md (1) · Joerg Albrecht, MD (1) · Kristin L Khan, MD (1)
PMID 37888917, PMID 40266487, PMID 34780095, PMID 34908192, PMID 36680419, PMID 39602139
2019 (2)